SoC therapy

ApprovedSmall molecule

AstraZeneca

SoC therapy is one of 63 small molecule programs targeting Wilson disease. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Wilson DiseaseActive, not recruiting

COVID-19Active, not recruiting

Type 2 DiabetesActive, not recruiting

Wilson DiseasePhase 3

Active, not recruiting

COVID-19Phase 2/Phase 3

Active, not recruiting

Type 2 DiabetesApproved

Active, not recruiting

Competition

Competitive Landscape

1931 competitors in COVID-19

#DrugCompanyPhaseTrials

SoC therapy

AstraZeneca

Approved

1 2

Bnt162b2

BioNTech

Preclinical

29 3

COVID-19 Vaccine

Moderna

Preclinical

27 4

Stivarga

Bayer

Preclinical

1 5

Aimovig

Amgen

Preclinical

1 6

Activella

Eli Lilly

Preclinical

—7

Piperacillin/tazobactam

Pfizer

Preclinical

1 8

Glucocorticoid

AbbVie

Preclinical

1 9

Nadroparin

GSK

Preclinical

1 10

Orap

Teva

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Wilson disease1 trial

Efficacy and Safety of ALXN1840 Administered for 48 Weeks Versus Standard of Care in Participants With Wilson Disease

Terminated· AstraZeneca logo

AstraZeneca·Phase 3·NCT03403205·214 enrolled

COVID-191 trial

Efficacy and Safety of Liposomal Lactoferrin in COVID-19 Patients With Mild-to-Moderate Disease and in COVID-19 Asymptomatic Patients

Completed·UUniversity of Rome Tor Vergata·Phase 2/3·NCT04475120·92 enrolled

Type 2 Diabetes1 trial

Nephropathy In Type 2 Diabetes and Cardio-renal Events

Completed·UUniversity of Campania Luigi Vanvitelli·Phase 4·NCT00535925·850 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for SoC therapy. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — SoC therapy compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for SoC therapy. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — AstraZeneca company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: AstraZeneca

SoC therapy

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Wilson disease1 trial

COVID-191 trial

Type 2 Diabetes1 trial

References

Drug Info

Quick Facts

Related News